CD38 and neoplasm: We compared the in vitro tumor cell‐killing effects of TE‐1146 with unconjugated α‐CD38 mAb and 3 anti‐MM drugs: i) daratumumab, ii) daratumumab combined with lenalidomide at a 1:6 molar ratio, analogous to the α‐CD38 mAb combined with 6 lenalidomide molecules in TE‐1146, and iii) lenalidomide (equal to the amount of lenalidomide used in the daratumumab/lenalidomide combination).